SeaStar's QUELIMMUNE Shows Promise in Halving Pediatric Sepsis Mortality Rates
June 27th, 2025 1:46 PM
By: Newsworthy Staff
SeaStar Medical's QUELIMMUNE therapy, approved by the FDA in 2024, has demonstrated the potential to reduce pediatric sepsis mortality rates by half, offering hope for critically ill children with acute kidney injury.
SeaStar Medical Holding Corp. has reported significant advancements in the treatment of pediatric patients suffering from acute kidney injury (AKI) due to sepsis, with its QUELIMMUNE therapy. Clinical trials leading to its 2024 FDA approval revealed that QUELIMMUNE could reduce mortality rates from 50% to 25% in this vulnerable population. The device targets the cytokine storm, a dysregulated immune response that exacerbates the condition of critically ill patients.
The effectiveness of QUELIMMUNE was highlighted in the case of Kurt, a young patient who faced multiple-organ failure after surgery. Treated at Cincinnati Children's Hospital Medical Center, Kurt's condition improved dramatically within 24 to 48 hours of receiving QUELIMMUNE therapy, avoiding the need for more invasive treatments like ECMO. His recovery, described as a 'Christmas miracle' by his father, underscores the potential of QUELIMMUNE to change outcomes for pediatric AKI patients.
Dr. Stuart L. Goldstein, the lead researcher for QUELIMMUNE's trials, noted the therapy's unprecedented success in not only saving lives but also in reducing the need for chronic dialysis among survivors. This breakthrough represents a significant leap forward in the treatment of pediatric sepsis and AKI, offering new hope to families and healthcare providers alike.
Source Statement
This news article relied primarily on a press release disributed by NewMediaWire. You can read the source press release here,
